Posted by Michael Wonder on 10 Jul 2022
Novavax Nuvaxovid COVID-19 vaccine conditionally authorised in the European Union for adolescents aged 12 through 17
5 July 2022 - Nuvaxovid COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe.
Novavax today announced that the European Commission has approved the expanded conditional marketing authorisation of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in the European Union for adolescents aged 12 through 17.
The approval follows the positive recommendation made by the European Medicines Agency's Committee for Medicinal Products for Human Use on 23 June 2022.
